Antiviral drug development is thus focusing ... The current standard-of-care treatment for the disease—interferon (IFN)-α in combination with the nucleoside analog ribavirin—is suboptimal ...

The researchers’ most notable finding was the contraction of the type I interferon (IFN) locus, which includes antiviral genes. 13 In most mammals, this region is large, containing many duplications.

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny ...

In vivo studies confirmed the greater antiviral efficacy of Jun13296 as compared to Jun12682. Jun13296 also reduced the activity of inflammatory cytokines like interleukin 6 (IL-6) and interferon ...

Licensed antiviral therapies are the interferon (IFN) alphas and the nucleoside analogue lamivudine. Both drugs enhance the rate at which HBeAg seroconversion takes place and thus reduce ...

Fumarate succinates mitochondrial antiviral-signalling protein, promoting its ability to drive type I interferon production and antiviral immunity. VISA/MAVS is the central adaptor in antiviral ...

Emerging data suggest that antiviral therapy in the third trimester ... drug in pregnant women clearly outweigh potential benefits. Interferon Abbreviations: FDA, U.S. Food and Drug Administration ...

New data from a number of clinical trials presented for the first time at the International Liver Congress™ 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents ...

ETH47 is a first-in-class mRNA antiviral therapy with broad-spectrum potential The project will generate key preclinical and clinical data to validate ETH47's potential in combating a broad ...